BLP and MDP pre-treated RACs enhance the disease-inducing ability of IRBP-specific T cells.

<p>IRBP1–20-specific T cells from the draining lymph nodes and spleens of donor B6 mice immunized with IRBP1–20 were stimulated with IRBP1–20 and irradiated naïve splenic APCs or RACs from either wild-type B6 or NOD2 knockout mice that had been left untreated or had been pre-treated with BLP and/or MDP as described in Fig. 2, then the T cell blasts (5×10⁶ cells/mouse) were transferred to naïve mice (n = 6/group). Eyes from the recipient mice were collected for histological evaluation on day 18 post-transfer. Histopathological lesions in the eyes of one representative mouse in each group (A) and average disease scores of both eyes in 6 individual mice that received T cells (<i>B</i>) are shown. **<i>p<</i>0.01 compared with RAC treated with medium, BLP, or MDP alone using Mann-Whitney U test.